Infinity Pharma

Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development segment. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. It focuses on its drug development segment. The company was founded by Steven H. Holtzman and Matthew D. Shair on March 22, 1995 and is headquartered in Cambridge, MA.

Infinity's (INFI) wider-than-estimated loss in Q3 displeases investors. Revenues too fall short of the mark.

Infinity (INFI) Q3 Loss Wider Than Expected, IPI-549 in Focus

Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q3 2019 Results - Earnings Call Transcript

Infinity (INFI) is currently focusing on the development of its lead immuno-oncology candidate IPI-549, an orally administered treatment that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma.

Infinity's (INFI) IPI-549 in Focus in a Crowded Cancer Space

Infinity (INFI) initiates two studies for IPI-549 -- a first-in-class, oral immuno-oncology product candidate.

Infinity Initiates 2 Studies for Lead Candidate IPI-549

Infinity (INFI) reported earnings 30 days ago. What's next for the stock?

Infinity (INFI) Down 22.5% Since Last Earnings Report: Can It Rebound?

Infinity (INFI) posts wider-than-expected loss in the second quarter of 2019 and misses sales estimates.

Infinity (INFI) Q2 Loss Wider Than Expected, Sales Miss

Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q2 2019 Results - Earnings Call Transcript

Infinity (INFI) delivered earnings and revenue surprises of -20.00% and -90.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Lags Revenue Estimates

Infinity (INFI) Up 6% Since Last Earnings Report: Can It Continue?

Infinity (INFI) posts wider-than-expected loss in the first quarter of 2019. Sales miss estimates in the quarter.

Infinity (INFI) Earnings and Sales Miss Estimates in Q1

Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q1 2019 Results - Earnings Call Transcript

Infinity (INFI) delivered earnings and revenue surprises of -380.00% and -78.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Lags Revenue Estimates

Infinity (INFI) Down 10% Since Last Earnings Report: Can It Rebound?

As of late, it has definitely been a great time to be an investor in Infinity Pharmaceuticals.

Will Infinity Pharmaceuticals Continue to Surge Higher?

Infinity (INFI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Infinity (INFI) Upgraded to Buy: Here's What You Should Know

Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q4 2018 Results - Earnings Call Transcript

News for Infinity Pharma Stock (INFI)